BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24813411)

  • 1. Acute and maintenance treatments for bipolar depression.
    Ketter TA
    J Clin Psychiatry; 2014 Apr; 75(4):e10. PubMed ID: 24813411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of FDA-approved treatment options in bipolar depression.
    McIntyre RS; Cha DS; Kim RD; Mansur RB
    CNS Spectr; 2013 Dec; 18 Suppl 1():4-20; quiz 21. PubMed ID: 24237641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
    Taylor DM; Cornelius V; Smith L; Young AH
    Acta Psychiatr Scand; 2014 Dec; 130(6):452-69. PubMed ID: 25283309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of bipolar depression: making sensible decisions.
    Citrome L
    CNS Spectr; 2014 Dec; 19 Suppl 1():4-11; quiz 1-3, 12. PubMed ID: 25407667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing benefits and harms of treatments for acute bipolar depression.
    Ketter TA; Miller S; Dell'Osso B; Calabrese JR; Frye MA; Citrome L
    J Affect Disord; 2014 Dec; 169 Suppl 1():S24-33. PubMed ID: 25533911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pros and cons of approved therapies for bipolar depression and ongoing unmet needs.
    McElroy SL
    J Clin Psychiatry; 2014 Oct; 75(10):e26. PubMed ID: 25373131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current landscape, unmet needs, and future directions for treatment of bipolar depression.
    Frye MA; Prieto ML; Bobo WV; Kung S; Veldic M; Alarcon RD; Moore KM; Choi DS; Biernacka JM; Tye SJ
    J Affect Disord; 2014 Dec; 169 Suppl 1():S17-23. PubMed ID: 25533910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics in bipolar depression: potential mechanisms of action.
    Yatham LN; Goldstein JM; Vieta E; Bowden CL; Grunze H; Post RM; Suppes T; Calabrese JR
    J Clin Psychiatry; 2005; 66 Suppl 5():40-8. PubMed ID: 16038601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of treatments for bipolar depression.
    Vázquez GH; Holtzman JN; Tondo L; Baldessarini RJ
    J Affect Disord; 2015 Sep; 183():258-62. PubMed ID: 26042634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical highlights in bipolar depression: focus on atypical antipsychotics.
    Calabrese JR; Elhaj O; Gajwani P; Gao K
    J Clin Psychiatry; 2005; 66 Suppl 5():26-33. PubMed ID: 16038599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on quetiapine in acute mania and depression associated with bipolar disorder.
    Dando TM; Keating GM
    CNS Drugs; 2006; 20(5):429-31. PubMed ID: 16696584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
    Bai Y; Yang H; Chen G; Gao K
    J Clin Psychopharmacol; 2020; 40(2):167-179. PubMed ID: 32134852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.
    Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
    Pharmacoeconomics; 2012 Jun; 30(6):513-30. PubMed ID: 22591130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
    Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
    J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics: newer options for mania and maintenance therapy.
    Vieta E; Goikolea JM
    Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the treatment of bipolar depression.
    Azorin JM; Kaladjian A
    Expert Opin Pharmacother; 2009 Feb; 10(2):161-72. PubMed ID: 19236191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.